Setd2‐deficient pancreatic tumor cells directly enhance neutrophil recruitment and reprogramming, thereby inhibiting the cytotoxicity of CD8+ T cells to foster tumor progression. This evidence concerns the gene SETD2 and pancreatic neoplasm.